Mid-cap Health Care company Natera has logged a -0.1% change today on a trading volume of 215,305. The average volume for the stock is 1,170,376.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Based in Austin, United States the company has 2,958 full time employees and a market cap of $4,687,010,816.
The company is now trading -45.67% away from its average analyst target price of $72.4 per share. The 15 analysts following the stock have set target prices ranging from $34.0 to $117.0, and on average give Natera a rating of buy.
Over the last 12 months NTRA shares have declined by -5.0%, which represents a difference of -28.0% when compared to the S&P 500. The stock's 52 week high is $63.0 per share and its 52 week low is $34.0. With its net margins declining an average -0.5% over the last 6 years, Natera declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-03-01 | 820,222 | -547,799 | -67 | 10.67 |
| 2022-02-25 | 625,486 | -471,716 | -75 | -27.12 |
| 2021-02-26 | 391,005 | -229,743 | -59 | -43.9 |
| 2020-03-02 | 302,328 | -124,827 | -41 | 18.0 |
| 2019-03-15 | 257,654 | -128,154 | -50 | 23.08 |
| 2018-03-15 | 210,939 | -136,314 | -65 |
